120 active trials 70 recruiting 37 Phase 3 31 disease areas 49 changes in 30 days
26 trials changed in the last 30 days: 0 stopped, 7 with notable changes, 19 with minor changes only.
Primary completion pushed from Dec 10, 2028 to Jul 8, 2030
Also in this update: Primary endpoint(s) modified; Completion pushed from Dec 21, 2029 to Jul 8, 2030
Regeneron PharmaceuticalsPhase 3 NCT07559513 Registry history of NCT07559513 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Mar 25, 2027 to Nov 8, 2028
Also in this update: Completion pushed from Nov 30, 2027 to Nov 8, 2028
Regeneron PharmaceuticalsPhase 1/2 NCT04590326 Registry history of NCT04590326 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Results posted: Sep 18, 2026
Regeneron PharmaceuticalsPhase 3 NCT06491914 Registry history of NCT06491914 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Regeneron PharmaceuticalsPhase 1 NCT07759167 Registry history of NCT07759167 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Regeneron PharmaceuticalsPhase 3 NCT07697599 Registry history of NCT07697599 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Primary completion pushed from Jul 25, 2029 to Sep 14, 2029; Completion pushed from Oct 16, 2029 to Dec 6, 2029
Regeneron PharmaceuticalsPhase 1/2 NCT07675824 Registry history of NCT07675824 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion moved earlier from Apr 22, 2032 to Jul 6, 2027
Also in this update: Enrollment closed, study ongoing; Trial sites reduced: 40 → 29 locations
Regeneron PharmaceuticalsPhase 1/2 NCT04077099 Registry history of NCT04077099 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Regeneron PharmaceuticalsPhase 1 NCT06669234 Registry history of NCT06669234 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Jan 21, 2027 to Apr 13, 2026; Final enrollment: 12343 participants (planned 3930)
Regeneron PharmaceuticalsNot specified NCT03936335 Registry history of NCT03936335 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Aug 20, 2027 to Jan 28, 2028
Also in this update: Completion pushed from Dec 8, 2027 to May 17, 2028
Regeneron PharmaceuticalsPhase 2 NCT07235917 Registry history of NCT07235917 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Jan 6, 2027 to May 5, 2027
Regeneron PharmaceuticalsPhase 1 NCT05259709 Registry history of NCT05259709 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 46 → 49 locations
And 1 more change in the last 30 days
Regeneron PharmaceuticalsPhase 3 NCT07213778 Registry history of NCT07213778 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 34 → 45 locations
And 1 more change in the last 30 days
Regeneron PharmaceuticalsPhase 3 NCT07626411 Registry history of NCT07626411 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 28 → 39 locations
And 2 more changes in the last 30 days
Regeneron PharmaceuticalsPhase 3 NCT07222761 Registry history of NCT07222761 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 84 → 87 locations
And 2 more changes in the last 30 days
Regeneron PharmaceuticalsPhase 2 NCT07175428 Registry history of NCT07175428 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 190 → 194 locations
And 2 more changes in the last 30 days
Regeneron PharmaceuticalsPhase 3 NCT06091865 Registry history of NCT06091865 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 6 → 12 locations
Regeneron PharmaceuticalsPhase 3 NCT07493304 Registry history of NCT07493304 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 17 → 20 locations
Regeneron PharmaceuticalsPhase 3 NCT07318610 Registry history of NCT07318610 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 14 → 19 locations
And 1 more change in the last 30 days
Regeneron PharmaceuticalsPhase 3 NCT07393282 Registry history of NCT07393282 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 18 → 35 locations
Regeneron PharmaceuticalsPhase 3 NCT07430956 Registry history of NCT07430956 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 14 → 20 locations
Regeneron PharmaceuticalsPhase 3 NCT07410117 Registry history of NCT07410117 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 5 → 18 locations
Regeneron PharmaceuticalsPhase 2 NCT07685808 Registry history of NCT07685808 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 6 → 9 locations
Regeneron PharmaceuticalsPhase 2 NCT07527910 Registry history of NCT07527910 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 27 → 30 locations
Regeneron PharmaceuticalsPhase 2 NCT07318597 Registry history of NCT07318597 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 1 → 5 locations
Regeneron PharmaceuticalsPhase 1 NCT07527923 Registry history of NCT07527923 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Mar 30, 2027 to Jul 28, 2027
Regeneron PharmaceuticalsNot specified NCT03428646 Registry history of NCT03428646 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-07 | NCT07863024 Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving… | Phase 1/2 | Not Yet Recruiting |
| 2026-10-06 | NCT07861152 Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants… | Phase 1 | Not Yet Recruiting |
| 2026-10-02 | NCT07854782 Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic… | Phase 3 | Not Yet Recruiting |
| 2026-09-30 | NCT07850921 REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant… | Phase 1/2 | Not Yet Recruiting |
| 2026-09-22 | NCT07832370 A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD) | Phase 1/2 | Not Yet Recruiting |
| 2026-09-21 | NCT07830329 Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe… | Phase 2 | Not Yet Recruiting |
| Phase 1 | 17 | |
| Phase 1/2 | 25 | |
| Phase 2 | 27 | |
| Phase 2/3 | 2 | |
| Phase 3 | 35 | |
| Phase 4 | 4 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07609940 | Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of… | Relapsed/Refractory Multiple Myeloma (RRMM) | Recruiting | 2026-09-25 |
| NCT07142343 | A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age… | CHAPLE Disease | Recruiting | 2026-04-13 |
| NCT06572228 | Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting… | Asthma | Active, Not Recruiting | 2026-05-22 |
| NCT07587658 | This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is… | Chronic Obstructive Pulmonary Disease (COPD) | Not Yet Recruiting | 2026-05-14 |
| Phase 3 | ||||
| NCT07015905 | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee… | Venous Thromboembolism (VTE) | Recruiting | 2026-10-08 |
| NCT07213778 | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee… | Symptomatic Venous Thromboembolism (VTE) | Recruiting | 2026-10-08 |
| NCT07222761 | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination… | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Recruiting | 2026-10-08 |
| NCT07626411 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | Atrial Fibrillation (AF) | Recruiting | 2026-10-08 |
| NCT05730036 | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab… | Relapsed Refractory Multiple Myeloma (RRMM) | Recruiting | 2026-10-07 |
| NCT06091865 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it… | Diffuse Large B-cell Lymphoma (DLBCL) | Recruiting | 2026-10-07 |
| NCT06149286 | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better… | Relapsed/Refractory Follicular Lymphoma | Recruiting | 2026-10-07 |
| NCT06246916 | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants… | Melanoma | Recruiting | 2026-10-07 |
| NCT07393282 | A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering… | High Risk Smoldering Multiple Myeloma (HR-SMM) | Recruiting | 2026-10-07 |
| NCT06091254 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works… | Follicular Lymphoma (FL) | Recruiting | 2026-10-06 |
| NCT07112378 | A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food… | Eosinophilic Esophagitis (EoE) | Recruiting | 2026-09-29 |
| NCT07410117 | REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis | Cancer-Associated Thrombosis (CAT) | Recruiting | 2026-09-29 |
| NCT07697599 | Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and… | Venous Thromboembolism (VTE) | Recruiting | 2026-09-29 |
| NCT05744921 | A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How… | Paroxysmal Nocturnal Hemoglobinuria | Recruiting | 2026-09-28 |
| NCT07493304 | Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants… | Venous Thromboembolism (VTE) | Recruiting | 2026-09-28 |
| NCT07318610 | Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With… | Peripheral Artery Disease (PAD) | Recruiting | 2026-09-25 |
| NCT06541704 | A Study Investigating Subcutaneously Administered Pozelimab in Combination With… | Age-related Macular Degeneration (AMD) | Recruiting | 2026-09-18 |
| NCT07430956 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation… | Atrial Fibrillation (AF) | Recruiting | 2026-09-17 |
| NCT06585410 | Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous… | Cutaneous Squamous Cell Carcinoma (CSCC) | Recruiting | 2026-09-16 |
| NCT07220785 | Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized… | Generalized Lipodystrophy | Recruiting | 2026-09-11 |
| NCT07675811 | A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and… | Allergic Conjunctivitis | Recruiting | 2026-08-12 |
Multiple Myeloma (11) · Non-Small Cell Lung Cancer (NSCLC) (10) · Lung Cancer (9) · Melanoma (6) · NASH / MASH (6) · Obesity (5) · Prostate Cancer (5) · Chronic Kidney Disease (4) · Non-Hodgkin Lymphoma (4) · Ovarian Cancer (4)